Article

jdsupra.com on 2019-11-21 22:19

FDA Approves 25th Biosimilar

On November 15, 2019, FDA approved Pfizer’s adalimumab product, a biosimilar to AbbVie’s Humira, marking the 25th approval of a biosimilar under the ...

Related news

FDA Approves First Rituximab Biosimilar jdsupra.com
California , United States , Switzerland
FDA Approves Sandoz’s Biosimilar Pegfilgrastim jdsupra.com
California , United States , Switzerland
FDA Approves Celltrion’s Trastuzumab Biosimilar jdsupra.com
California , United States , Switzerland
FDA Approves Samsung Bioepis’s Trastuzamab Biosimilar jdsupra.com
California , United States , Switzerland
FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADA jdsupra.com
California , United States , Switzerland
FDA approves a fourth biosimilar of HERCEPTIN jdsupra.com
California , United States , Switzerland
FDA Approves First Biosimilar: Sandoz’s Zarxio®jdsupra.com
United States
FDA Approves Second Pegfilgrastim Biosimilar, a First for Coherus jdsupra.com
California , United States , Switzerland
FDA Approves First Avastin Biosimilar jdsupra.com
FDA Approves Third Biosimilar Product jdsupra.com
FDA Approves Pfizer’s EPO Biosimilar jdsupra.com
FDA Approves Another Interchangeable Biosimilar jdsupra.com
FDA Approves Rheumatoid Arthritis Biosimilar wsj.com
Europe , Australia , Mexico , Canada
FDA Approves First Biosimilar Drug wsj.com
Europe , China , Wall Street
FDA Approves Sandoz Filgrastim Biosimilar jdsupra.com
FDA Approves Lantus® Interchangeable Biosimilar jdsupra.com
China NMPA Approves Adalimumab Biosimilar jdsupra.com
California , United States , Switzerland , China
Sandoz Obtains FDA Approval for Adalimumab Biosimilar jdsupra.com
California , United States , Switzerland
FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)jdsupra.com
California , United States , Switzerland
FDA Implements Biosimilar Action Plan to Boost Biosimilar Competition jdsupra.com
California , United States , Switzerland